SODIUM ACETATE INJECTION USP 328 MG — DIN 02181746
SODIUM ACETATE 328 MG · OMEGA LABORATORIES LIMITED · Solution · wholesale supply in Canada
Health Canada status: MARKETED
What is SODIUM ACETATE INJECTION USP?
SODIUM ACETATE INJECTION USP 328 MG contains SODIUM ACETATE 328 MG. It is listed in the Health Canada Drug Product Database under DIN 02181746, held by OMEGA LABORATORIES LIMITED, supplied as Solution for Intravenous administration. Health Canada currently lists it as marketed, status dated 11-Jan-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SODIUM ACETATE INJECTION USP used for?
Sodium Acetate Injection USP is indicated as a source of sodium, for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Sodium Acetate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Sodium Acetate, across 5 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 1 | 1 | SODIUM ACETATE INJECTION, USP | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 1 | 1 | SODIUM ACETATE INJECTION USP | Sourceable in Canada |
| BAXTER CORPORATION | 1 | 0 | 16.4% SODIUM ACETATE INJECTION, USP | No marketed DIN |
| LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | 1 | 0 | SODIUM ACETATE INJ 328MG/ML USP | No marketed DIN |
| SABEX INC | 1 | 0 | SODIUM ACETATE INJ 328MG/ML USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 328 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Pack configuration (monograph) | Single use vials of 50 mL in boxes of 10. |
| Storage | Protect from light. Store between 15 °C and 30 °C. Do not freeze. Discard unused portion. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Sodium Acetate |
|---|---|
| ATC code | B05XA08 |
| AHFS class | 40:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02181746 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2181746 |
| Brand name | SODIUM ACETATE INJECTION USP |
| Generic / active ingredient | SODIUM ACETATE 328 MG |
| Market authorization holder | OMEGA LABORATORIES LIMITED |
| Health Canada schedule | ETHICAL |
| ATC code | B05XA08 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05XA |
| Current status | MARKETED |
| Status date | 11-Jan-2024 |
| Original market date | 1999-05-28 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Sodium Acetate Injection USP is administered intravenously only after dilution in a larger volume of intravenous fluids. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of milliequivalents (mEq) of sodium with an equal number of acetate. Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Sodium Acetate Injection USP is contraindicated in patients with hypernatremia or fluid retention.
Warnings and precautions
Sodium Acetate Injection USP must be diluted before use. To avoid sodium overload and water retention, infuse sodium-containing solutions slowly. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. The intravenous administration of this solution (after appropriate dilution) can cause fluid and/or solute overloading resulting in dilution of other serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excessive administration of potassium-free solutions may result in significant hypokalemia.
Is Sodium Acetate in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| SODIUM ACETATE INJECTION, USP | 328 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02139529 |
| 16.4% SODIUM ACETATE INJECTION, USP | 16.4 % | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 02247204 |
| SODIUM ACETATE INJ 328MG/ML USP | 328 MG | LIQUID | SABEX INC | CANCELLED POST MARKET | 00780642 |
| SODIUM ACETATE INJ 328MG/ML USP | 328 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | 01944843 |
2 · Same class — other molecules in ATC B05XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Sodium Chloride | 0.45% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION · 0.9% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION, USP · +23 more | 37 | 11 | Yes |
| Potassium Chloride | POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE, USP (2 MEQ/ML) · POTASSIUM CHLORIDE INJ 149MG/ML USP · +7 more | 17 | 7 | Yes |
| Sodium Bicarbonate | SODIUM BICARBONATE 5% INJ 50MG/ML USP · SODIUM BICARBONATE 5% INJ 5GM/100ML USP · SODIUM BICARBONATE INJ 4.2% · SODIUM BICARBONATE INJ 7.5% · +6 more | 18 | 5 | Yes |
| Electrolytes In Comb With Other Drugs | ADDNUTRIV · MICRO +4 REGULAR STRENGTH · MICRO PLUS 4 CONCENTRATE · MICRO PLUS 5 CONCENTRATE · +10 more | 14 | 5 | Yes |
| Calcium Gluconate | 2% CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE INJECTION USP 10% · CALCIUM GLUCONATE INJECTION, USP 10% | 5 | 5 | Yes |
| Magnesium Sulphate | MAGNESIUM SULFATE IN WATER FOR INJECTION · MAGNESIUM SULFATE INJ 50% · MAGNESIUM SULFATE INJECTION 50% USP · MAGNESIUM SULFATE INJECTION BP · +3 more | 9 | 4 | Yes |
| Zinc Sulfate | MICRO ZN · ZINC SULFATE INJECTION, USP | 4 | 4 | Yes |
| Potassium Phos Incl Comb W/0th Pot. Salts | POTASSIUM PHOSPHATE INJ 3MMP/ML · POTASSIUM PHOSPHATE MONOBASIC INJECTION · POTASSIUM PHOSPHATES · POTASSIUM PHOSPHATES INJ · +1 more | 5 | 3 | Yes |
| Calcium Chloride | CALCIJECT INJ 100MG/ML · CALCIUM CHLORIDE INJECTION BP · CALCIUM CHLORIDE INJECTION USP · CALCIUM-35 0.25 - 10 · +1 more | 5 | 2 | Yes |
| Sodium Acetate | 16.4% SODIUM ACETATE INJECTION, USP · SODIUM ACETATE INJ 328MG/ML USP · SODIUM ACETATE INJECTION USP · SODIUM ACETATE INJECTION, USP | 5 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05XC | Vitamins | 9 | 2 |
| B05XX | Trometamol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is SODIUM ACETATE INJECTION USP called?
Also recorded in Canada as: 20 ML sodium acetate 2 MEQ/ML Injection (US), 50 ML sodium acetate 4 MEQ/ML Injection (US), sodium acetate 2 MEQ/ML Injectable Solution (US), sodium acetate 4 MEQ/ML Injectable Solution (US), DEXTROSE, SODIUM ACETATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, AND POTASSIUM PHOSPHATE, DIBASIC (US), DEXTROSE, SODIUM CHLORIDE, SODIUM ACETATE ANHYDROUS, SODIUM GLUCONATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE (US), SODIUM ACETATE (US), SODIUM ACETATE ANHYDROUS (US), SODIUM ACETATE INJECTION, USP, 200 MEQ/100 ML (US), SODIUM ACETATE INJECTION, USP, 400 MEQ/100 ML (US), SODIUM CHLORIDE, CALCIUM CHLORIDE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, AND SODIUM ACETATE ANHYDROUS (US), Sodium Acetate Injection (US), Sodium Acetate (GLOBAL), Sodium Acetate (UK), Sodium Acetate Hydrate (JP).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.